NASDAQ:ZNTL Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis $1.96 +0.16 (+8.61%) As of 11:34 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ZNTL alerts:Sign Up Key Stats Today's Range$1.79▼$1.9850-Day Range$1.71▼$4.1152-Week Range$1.28▼$6.95Volume315,091 shsAverage Volume1.53 million shsMarket Capitalization$140.11 millionP/E RatioN/ADividend YieldN/APrice Target$7.75Consensus RatingModerate Buy Company Overview Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments. Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response. The company has evaluated azenosertib in multiple cancer types and continues to investigate its potential as a treatment for solid tumors and hematologic malignancies. Zentalis has also developed additional oncology candidates aimed at targets such as BCL-2 and other mechanisms relevant to cancer biology. The company was established in 2014 and is headquartered in San Diego, California. Its development programs are conducted through clinical research and collaborations with medical institutions and other research organizations. Zentalis is led by Kimberly L. Blackwell, M.D., who serves as chief executive officer and has experience in oncology drug development and commercial strategy.AI Generated. May Contain Errors. Read More Zentalis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreZNTL MarketRank™: 4.503616042075 of 5 starsZentalis Pharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 29th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingZentalis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 7 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialZentalis Pharmaceuticals has a consensus price target of $7.75, representing about 312.7% upside from its current price of $1.88.Amount of Analyst CoverageZentalis Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zentalis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($2.15) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zentalis Pharmaceuticals is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zentalis Pharmaceuticals is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZentalis Pharmaceuticals has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.30% of the float of Zentalis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverZentalis Pharmaceuticals has a short interest ratio ("days to cover") of 3.49, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zentalis Pharmaceuticals has recently decreased by 15.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZentalis Pharmaceuticals does not currently pay a dividend.Dividend GrowthZentalis Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.79 News SentimentZentalis Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Zentalis Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest5 people have searched for ZNTL on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows5 people have added Zentalis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $15,172,500.00 in company stock, which represents 11.2726% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Zentalis Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,172,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders3.80% of the stock of Zentalis Pharmaceuticals is held by insiders.Percentage Held by InstitutionsZentalis Pharmaceuticals has minimal institutional ownership at this time.Read more about Zentalis Pharmaceuticals' insider trading history. Receive ZNTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZNTL Stock News HeadlinesZentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdatesNovember 9 at 4:05 PM | globenewswire.comZentalis Pharmaceuticals (ZNTL) Expected to Post Quarterly Earnings on TuesdayNovember 9 at 1:56 AM | americanbankingnews.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 11 at 1:00 AM | Weiss Ratings (Ad)Zentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 3, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 2, 2026 | globenewswire.comZentalis Pharmaceuticals Announces Median Overall Survival Data In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer From DENALI Part 1bOctober 24, 2026 | marketscreener.comMZentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ...October 23, 2026 | finance.yahoo.comZentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026October 23, 2026 | globenewswire.comSee More Headlines ZNTL Stock Analysis - Frequently Asked Questions How have ZNTL shares performed this year? Zentalis Pharmaceuticals' stock was trading at $1.35 at the beginning of 2026. Since then, ZNTL stock has increased by 39.1% and is now trading at $1.8780. How were Zentalis Pharmaceuticals' earnings last quarter? Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) released its quarterly earnings results on Monday, November, 9th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.20. When did Zentalis Pharmaceuticals IPO? Zentalis Pharmaceuticals (ZNTL) raised $156 million in an IPO on Friday, April 3rd 2020. The company issued 9,180,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO. Who are Zentalis Pharmaceuticals' major shareholders? Zentalis Pharmaceuticals' top institutional investors include Eiger Wealth Management LLC (0.16%), Russell Investments Group Ltd. (0.11%) and Jefferies Financial Group Inc. (0.06%). Insiders that own company stock include Group Walters, Matrix Capital Management Comp, Cam Gallagher, Melissa B Epperly, Scott Dunseth Myers, Kimberly Blackwell, Mark Lackner, Jan Skvarka, Vincent Vultaggio and Ingmar Bruns. View institutional ownership trends. How do I buy shares of Zentalis Pharmaceuticals? Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zentalis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Tesla (TSLA), Iovance Biotherapeutics (IOVA), Nkarta (NKTX), Rocket Pharmaceuticals (RCKT), NIO (NIO), Alibaba Group (BABA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/09/2026Today11/11/2026Stifel 2026 Healthcare Conference 202611/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, ZNTL's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZNTL CIK1725160 Webwww.zentalis.com Phone212-433-3791FaxN/AEmployees106Year Founded2014Price Target and Rating Average Price Target for Zentalis Pharmaceuticals$7.75 High Price Target$11.00 Low Price Target$4.00 Potential Upside/Downside+302.6%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$137.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-78.34% Return on Assets-56.12% Debt Debt-to-Equity RatioN/A Current Ratio4.82 Quick Ratio4.82 Sales & Book Value Annual Sales$67.43 million Price / Sales2.05 Cash FlowN/A Price / Cash FlowN/A Book Value$2.99 per share Price / Book0.64Miscellaneous Outstanding Shares71,670,000Free Float68,948,000Market Cap$137.96 million OptionableOptionable Beta1.91 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ZNTL) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredSocial Security’s trust fund runs short in 2032. Guess who controls Congress.Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. Af...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZNTL Stock Alerts